Methods and compositions for treating wounds utilizing chitosan compounds
AssigneeSynedgen, Inc.
InventorsShenda Baker, William P. Wiesmann, Ruth Baxter
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.
Claims29
1-65. (canceled)
A method of treating mucositis or ulceration, or a symptom of mucositis or ulceration, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
- thereby treating mucositis or ulceration, or the symptom of mucositis or ulceration.
A method of treating a symptom of a chronic disease, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
- thereby treating the symptom of the chronic disease.
A method of treating a wound in a subject, wherein the wound is a result of an acute or chronic infection, or the wound is not infected, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
- thereby treating the wound.
(canceled)
A method of treating a subject who has been treated or is being treated for cancer with a cancer therapy, the method comprising administering to the subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
- thereby treating the subject.
71-73. (canceled)
A method of treating a subject receiving a surgical procedure or having undergone a surgical procedure, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
- thereby treating the subject.
75-79. (canceled)
Dependencies are inferred from the claim text.